SCHEMBL25375347

SCHEMBL25375347

Cc1ccc(CNCc2ccccc2)nc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 3/20 0.45
ALDH1A1 P00352 3/20 0.45
KDM4E B2RXH2 1/20 0.45
HTT P42858 2/20 0.44
MEN1 O00255 5/20 0.44
KMT2A Q03164 5/20 0.44
TDP1 Q9NUW8 1/20 0.44
TP53 P04637 1/20 0.44
THRB P10828 1/20 0.44
MAPT P10636 2/20 0.43
LMNA P02545 2/20 0.43
BCHE P06276 1/20 0.42
NOS2 P35228 1/20 0.41
KDM4A O75164 1/20 0.41
KDM4B O94953 1/20 0.41
KDM5C P41229 1/20 0.41
KDM5B Q9UGL1 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MAPK1 P28482 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14477280 0.80 CCR1 (0.43) HTR1ANOS2
SCHEMBL25522228 0.79 TLR7 (0.41) HTR1AKDM4ESMN1; SMN2
SCHEMBL25376070 0.79 MEN1 (0.44) ALDH1A1KDM4EHTTMEN1KMT2A
SCHEMBL25373983 0.79 MEN1 (0.44) ALDH1A1MEN1KMT2ATDP1TP53
SCHEMBL30482155 0.79 MEN1 (0.44) ALDH1A1KDM4EHTTMEN1KMT2A
SCHEMBL13562421 0.78 ALDH1A1 (0.46) ALDH1A1KDM4EHTTMEN1KMT2A
SCHEMBL7625869 0.77 HTT (0.63) HTTMEN1KMT2ATDP1TP53
SCHEMBL18843420 0.77 KDM4A (0.43) ALDH1A1MEN1KMT2ATDP1THRB
SCHEMBL8346148 0.76 L3MBTL1 (0.55) ALDH1A1KDM4EMEN1KMT2ATP53
SCHEMBL29466164 0.76 L3MBTL1 (0.55) ALDH1A1KDM4EMEN1KMT2ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136594-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-05-01 US disclosed
EP-4469438-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 EP disclosed
WO-2023146987-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
WO-2023146987-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136594-A1 COMPOUNDS AND METHODS OF USE CNKSR1, UGT1A1, REV1 HTR1A 653/4885ALDH1A1 29/4885KDM4E 1639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.